We are advised by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. that journalists and other readers should disregard the news release, "Third Indication for Kelun-Biotech's TROP2 ADC Sac-TMT Approved for Marketing by NMPA in EGFRm NSCLC Following Progression on EGFR-TKI Therapy", issued 11-Oct-2025 over PR Newswire, as the release contained erroneous information. (Kelunbiotech said a revised release will be issued later. )
source: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
【說說心理話】疫情封關期間，獨自陪絕症丈夫赴日求醫，24/7貼身照顧，如何處理壓力及情緒？► 即睇
